Tissue volume reduction

• US 6,682,520 B2
• Filed: 04/20/2001
• Issued: 01/27/2004
• Est. Priority Date: 08/23/1999
• Status: Expired due to Term

• Current Assignee: Pulmonx Pulmonx
• Original Assignee: Bistech Incorporated
• Inventors: Ingenito, Edward P.
• Primary Examiner(s): Casler, Brian L.
• Assistant Examiner(s): WILLIAMS, CATHERINE SERKE
• Application Number:
  US09/839,253
• Publication Number:
  US 20010051799A1
• Time in Patent Office: 1,012 Days
• Field of Search: 604/48, 604/500, 604/27, 604/28, 604/93.01, 604/264, 604/275, 604/523, 604/514, 604/518, 606/213-221, 606/229-232
• US Class Current: 604/514
• CPC Class Codes: A61B 1/2676 Bronchoscopes
• CPC Class Codes: A61B 17/00491 Surgical glue applicators surgical adhesives A61L24/00; two-component delivery syringes A61M5/19
• CPC Class Codes: A61B 17/12022 Occluding by internal devices, e.g. balloons or releasable wires plugging an opening in the wall of an organ A61B17/0057; occluders for the cervical canal A61F6/146; vas deferens occluders A61F6/20
• CPC Class Codes: A61B 17/12104 in an air passage
• CPC Class Codes: A61B 17/12136 Balloons
• CPC Class Codes: A61B 17/12186 liquid materials adapted to be injected
• CPC Class Codes: A61B 2017/00495 for two-component glue
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/1858 Platelet-derived growth factor [PDGF]
• CPC Class Codes: A61K 38/363 Fibrinogen
• CPC Class Codes: A61K 38/4833 Thrombin (3.4.21.5)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

Devices, compositions, and methods for achieving non-surgical lung volume reduction (e.g., bronchoscopic lung volume reduction (BLVR)) are described. BLVR can be carried out by collapsing a region of the lung, adhering one portion of the collapsed region to another, and promoting fibrosis in or around the adherent tissue.

Claims

1. A method of reducing lung volume in a patient, the method comprising:

(a) advancing a bronchoscope into a region of the lung targeted for reduction; and

(b) introducing biological or biochemical material into the targeted region through the bronchoscope to reduce the volume of the targeted region by inducing collapse of the targeted region;

promoting adhesion between one portion of the collapsed lung and another; and

promoting fibrosis in or around the collapsed region of the lung.

2. The method of claim 1, wherein the biological or biochemical material comprises fibrin or fibrinogen.

3. The method of claim 2, wherein the biological or biochemical material further comprises a polypeptide growth factor.

4. The method of claim 3, wherein the polypeptide growth factor is a fibroblast growth factor or a transforming growth factor beta-like (TGFβ

-like) polypeptide.

5. The method of claim 1, wherein the biological or biochemical material comprises fibrinogen and promoting adhesion between one portion of the collapsed lung and another is facilitated by administration of a fibrinogen activator.

6. The method of claim 5, wherein the fibrinogen activator is thrombin.

7. The method of claim 2, wherein the fibrinogen comprises 3-12% fibrinogen.

8. The method of claim 7, wherein the fibrinogen comprises approximately 10% fibrinogen.

9. The method of claim 1, wherein promoting fibrosis in or around the collapsed region of the lung is achieved by administering a polypeptide growth factor.

10. The method of claim 9, wherein the polypeptide growth factor is a fibroblast growth factor (FGF).

11. The method of claim 10, wherein the FGF is basic fibroblast growth factor (bFGF).

12. The method of claim 9, wherein the polypeptide growth factor is transforming growth factor-beta (TGF-β

).

13. The method of claim 1, further comprising, prior to collapsing a region of the lung, inflating the region with absorbable gas.

14. A method for reducing lung volume in a patient, the method comprising

(a) advancing a bronchoscope into a region of the lung targeted for reduction;

and

(b) introducing biological or biochemical material into the targeted region through the bronchoscope to reduce the volume of the targeted region,

wherein the biological or biochemical material introduced through the bronchoscope induces collapse of the targeted region; and

promotes adhesion between one collapsed portion of the lung and another.

15. The method of claim 14, wherein the biological or biochemical material further promotes fibrosis in or around the collapsed region of the lung.

16. The method of claim 14, wherein the biological or biochemical material comprises fibrin or fibrinogen.

17. The method of claim 14, wherein the biological or biochemical material further comprises a polypeptide growth factor.

18. The method of claim 17, wherein the polypeptide growth factor is a fibroblast growth factor or a transforming growth factor beta-like (TGFβ

-like) polypeptide.

19. The method of claim 14, wherein the biological or biochemical material is fibrinogen and the method further comprises introducing a fibrinogen activator into the targeted region.

20. The method of claim 19, wherein the fibrinogen activator is thrombin.

21. The method of claim 14, wherein the biological or biochemical material is fibrinogen, the fibrinogen being administered in a formulation containing 3-12% fibrinogen.

22. The method of claim 21, wherein the formulation comprises approximately 10% fibrinogen.

23. The method of claim 14, further comprising reducing the risk of infection by administration of an antibiotic.

24. The method of claim 23, wherein the antibiotic is administered together with the biological or biochemical material.

25. A non-surgical method for performing lung volume reduction, the method comprising:

(a) collapsing a region of the lung;

(b) adhering one portion of the collapsed region to another; and

(c) promoting fibrosis in or around the collapsed region of the lung, wherein promoting fibrosis in or around the collapsed region of the lung is achieved by administering a polypeptide growth factor.

26. The method of claim 25, wherein the polypeptide growth factor is a fibroblast growth factor (FGF).

27. The method of claim 25, wherein the FGF is basic fibroblast growth factor (bFGF).

28. The method of claim 25, wherein the polypeptide growth factor is transforming growth factor-beta (TGF-β

).

29. The method of claim 25, further comprising reducing the risk of infection by administration of an antibiotic.

30. The method of claim 29, wherein the antibiotic is administered together with fibrinogen, fibrin, or a fibrinogen activator.

31. The method of claim 25, further comprising, prior to collapsing a region of the lung, inflating the region with absorbable gas.

32. The new method of claim 31, wherein the absorbable gas is at least 90% oxygen.